论文部分内容阅读
目的探讨人尿激肽原酶治疗急性缺血性脑卒中患者的临床效果。方法选取2014年1月至2015年1月医院收治的66例急性缺血性脑卒中患者作为研究对象,按随机数字表法将其分为对照组和试验组,各33例。对照组患者接受常规临床治疗,试验组患者在对照组基础上采用人尿激肽原酶进行治疗,比较两组患者超敏c反应蛋白(hs-CRP)水平、神经功能缺损情况及临床治疗效果。结果治疗后,试验组患者的hs-CRP水平、美国国立卫生研究院卒中量表(NIHSS)评分明显低于对照组,差异有统计学意义(P<0.05);试验组患者治疗的总有效率明显高于对照组,差异有统计学意义(P<0.05)。结论采用人尿激肽原酶治疗急性缺血性脑卒中患者临床效果明显,能够有效改善患者神经功能缺损情况。
Objective To investigate the clinical efficacy of human urokinase in the treatment of patients with acute ischemic stroke. Methods Sixty-six patients with acute ischemic stroke admitted from January 2014 to January 2015 in our hospital were selected as the research objects. According to the random number table, they were divided into control group and trial group, with 33 cases in each group. The patients in the control group received routine clinical treatment. The patients in the test group were treated with human kallikrein on the basis of the control group. The levels of hs-CRP, neurological deficits and clinical effects were compared between the two groups . Results After treatment, the hs-CRP level in the test group and NIHSS score in the experimental group were significantly lower than those in the control group (P <0.05). The total effective rate of treatment in the experimental group The difference was statistically significant (P <0.05). Conclusion The clinical efficacy of human kallikrein in the treatment of patients with acute ischemic stroke is obvious, which can effectively improve the neurological deficit in patients.